M42 announces strategic investment, partnership with leading biotech Juvenescence
As part of this investment, M42 and Juvenescence will form a strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases.
The strategic partnership and investment underlines M42's commitment to advancing its capabilities in drug discovery and development following the creation of its Integrated Health Solutions and Life Sciences platforms under its new operating structure announced recently. Leveraging M42's deep expertise in genomics, biobanking, and clinical trial infrastructure alongside Juvenescence's cutting-edge AI-enabled discovery technology and extensive drug development expertise, this collaboration will drive breakthroughs in life sciences research, enhance disease understanding, and enable fast-tracking of clinical trials.
As well as identifying novel drug targets and therapeutics, the partnership will explore collaboration in R&D with leading academic and research organizations globally and support the development of M42's biotechnology strategy in Abu Dhabi. A Joint Steering Committee comprised of senior executives from both companies will oversee the execution of this partnership.
Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said, "With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi's push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges. With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it's about impact – on lives, on science and on the future of health.'
Dr Fahed Al Marzooqi, Chief Executive Officer of M42's Integrated Health Solutions platform and Acting Chief Executive Officer of M42's AI Life Sciences platform, added, 'Our partnership with Juvenescence is a crucial step toward redefining healthcare through AI-driven drug discovery and biotechnology. By uniting AI innovation with biotech expertise, we're not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress—delivering transformative therapies from Abu Dhabi to the world.'
Dr. Richard Marshall, Chief Executive Officer at Juvenescence, said, 'We are delighted to be working together with M42. This powerful partnership will combine M42's expertise in AI, technology, and genomics with Juvenescence's unrivalled ability to discover and develop innovative drugs for age-related disease. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.'
The collaboration will see Juvenescence's team of globally recognized scientists and industry leaders - with more than 150 years of cumulative experience in drug discovery and development* work with M42 to build its own innovative therapeutics pipeline.
By partnering with Juvenescence, M42 is building on its genomics expertise developed in collaboration with the Department of Health Abu Dhabi (DoH) to further drive advancements in disease understanding and precision medicine. M42's Omics Center of Excellence - the largest outside the U.S. - supports the Emirati Genome Project (EGP), which has already sequenced over 800,000 whole genomes and has a goal of sequencing one million local Emiratis. Additionally, M42's Abu Dhabi Biobank (ADBB) has stored over 900,000 samples, a repository that will be an invaluable resource for future biomedical research in the UAE and beyond.
The partnership aligns with Abu Dhabi's broader vision to become a world-class destination for health innovation and to build a life sciences hub as part of its economic diversification agenda.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Campaign ME
17-07-2025
- Campaign ME
Edelman UAE makes key leadership appointments
Edelman has announced new leadership appointments across its UAE team in an effort to reinforce its specialist capabilities in Health, Crisis & Risk, and Brand. These internal moves promotions aim to reflect Edelman's ongoing investment in integrated, sector-led communications and the strength of its senior talent across the region. Lauren Brush has assumed the role of Head of Health, bringing a track record of advising high-profile global stakeholders, including the Saudi Ministry of Health and leading U.S.-based medical associations. Her work spans pandemic response, BRCA testing, and the launch of the UAE's first-ever telemedicine portal. Already a key advisor on Edelman's partnership with M42 and its expansive portfolio, Brush will now lead the development of the firm's health offer in the region, helping clients navigate an increasingly high-impact and rapidly shifting sector. Chase Burns has been appointed Head of Crisis & Risk, expanding his role within Edelman's Corporate Practice. He currently leads the work for the Abu Dhabi Investment Office (ADIO), Hub71 and ATRC. With more than 15 years of experience both in-house and advising clients through high-stakes, reputationally sensitive situations across aviation, advanced technology and sovereign investment, Burns has overseen responses to aircraft groundings, geopolitical attacks, and pandemic-related disruptions. As scrutiny intensifies and exposure to misinformation and disinformation, operational disruption, and geopolitical risks grows, Burns will lead the development of Edelman's integrated crisis and risk advisory services in the region, helping clients anticipate, navigate and recover from complex situations, while also representing the region within Edelman's global crisis leadership team. Lastly, Deepanshi Tandon has been appointed Head of Brand for Edelman UAE. In her role, she will lead the Brand practice, building on Edelman's expertise in creating earned-first, trusted brands that drive influence and shape culture. She brings more than 15 years of experience and has led several global brands across markets and sectors, spearheading strategic, creative, and culturally resonant work. Tandon currently leads work for clients such as PepsiCo and Nissan Middle East and has played a central role in shaping brand reputation strategies and leading integrated, multi-channel campaigns that drive cultural relevance and impact. On the appointments, Omar Qirem, CEO, Edelman Middle East, said: 'These leadership updates reflect both our investment in specialist talent and our commitment to developing leadership from within. Lauren, Chase and Deepanshi bring a powerful combination of subject matter expertise, client trust, and integrated thinking that will be instrumental to our next chapter of growth in the region.' The global communications firm operates wholly owned offices in Abu Dhabi, Dubai, and Riyadh as part of Edelman's broader Middle East network.
Zawya
09-07-2025
- Zawya
M42, GE HealthCare join forces to advance AI-Enabled Patient Care
M42, a global health leader powered by technology, artificial intelligence and genomics, will collaborate with GE HealthCare, a global innovator in medical technology, pharmaceutical diagnostics and integrated, cloud-first AI-enabled digital solutions, to enhance diagnostic precision and deliver more personalised patient outcomes, marking a significant step forward in the future of smart healthcare in the UAE. M42 and GE HealthCare will harness their combined strengths in advanced AI-powered solutions and explore collaborative go-to-market initiatives to deliver smarter, more connected healthcare in the region, with a focus on improving both clinical and operational efficiency. Leveraging M42's advanced AI, data and technology platforms alongside GE HealthCare's deep expertise in medical technology and product development, this collaboration will focus on co-developing innovative solutions to tackle pain points in healthcare systems and help support business and operational outcomes. By integrating AI with multimodal data analysis, M42 and GE HealthCare aim to accelerate product development and further position the region as a growing hub for life sciences innovation. Dimitris Moulavasilis, Group Chief Executive Officer at M42, said, 'Our collaboration with GE HealthCare is another step forward in M42's journey to disrupt traditional healthcare systems and positively impact people. By combining our strengths, we will be developing and deploying tech-enabled solutions to tackle the toughest challenges in the healthcare sector, delivering real, measurable outcomes for both patients and health systems. Together, we aren't just reimagining the future of precision medicine and smart care; we're building it here in the UAE and scaling it to the world.' Konstantinos Deligiannis, EAGM (Eurasian and African Growth Markets), President of GE HealthCare, added, 'We are committed to driving precision care through innovation and collaboration. Our collaboration with M42 represents a powerful convergence of advanced AI, data, and clinical expertise, and is a testament to our shared vision of delivering smarter, more connected healthcare solutions that improve outcomes for patients everywhere.' Leveraging the UAE's innovation-friendly ecosystem, this partnership reflects the country's ambition to lead in global health innovation by advancing world-class, patient-centered care. In partnering with a global health tech giant, M42 continues to progress smarter, more personalised care for communities in the UAE and beyond. M42's Diaverum business has taken 30 years of dialysis know-how to develop an AI-powered digital platform that not only reduces hospital stays, but has decreased the mortality rate, predicting thrombotic events before they occur. M42 has also developed and deployed Med42 LLM model, a large language model designed for clinical use cases and available for research use as an open-source solution. The company's AIRIS-TB conducts 2,000 AI-powered chest X-ray examinations daily to screen for tuberculosis against 200 conducted via conventional methods.
Al Etihad
09-07-2025
- Al Etihad
M42, GE HealthCare join forces to advance AI-enabled patient care
9 July 2025 15:27 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, artificial intelligence and genomics, will collaborate with GE HealthCare, a global innovator in medical technology, pharmaceutical diagnostics and integrated, cloud-first AI-enabled digital solutions, to enhance diagnostic precision and deliver more personalized patient outcomes, marking a significant step forward in the future of smart healthcare in the UAE.M42 and GE HealthCare will harness their combined strengths in advanced AI-powered solutions and explore collaborative go-to-market initiatives to deliver smarter, more connected healthcare in the region, with a focus on improving both clinical and operational M42's advanced AI, data and technology platforms alongside GE HealthCare's deep expertise in medical technology and product development, this collaboration will focus on co-developing innovative solutions to tackle pain points in healthcare systems and help support business and operational outcomes. By integrating AI with multimodal data analysis, M42 and GE HealthCare aim to accelerate product development and further position the region as a growing hub for life sciences Moulavasilis, Group Chief Executive Officer at M42, said: 'Our collaboration with GE HealthCare is another step forward in M42's journey to disrupt traditional healthcare systems and positively impact people. By combining our strengths, we will be developing and deploying tech-enabled solutions to tackle the toughest challenges in the healthcare sector, delivering real, measurable outcomes for both patients and health systems. Together, we aren't just reimagining the future of precision medicine and smart care; we're building it here in the UAE and scaling it to the world.'Konstantinos Deligiannis, EAGM (Eurasian and African Growth Markets), President of GE HealthCare, added: 'We are committed to driving precision care through innovation and collaboration. Our collaboration with M42 represents a powerful convergence of advanced AI, data, and clinical expertise, and is a testament to our shared vision of delivering smarter, more connected healthcare solutions that improve outcomes for patients everywhere.' Leveraging the UAE's innovation-friendly ecosystem, this partnership reflects the country's ambition to lead in global health innovation by advancing world-class, patient-centred care. In partnering with a global health tech giant, M42 continues to progress smarter, more personalised care for communities in the UAE and beyond. M42's Diaverum business has taken 30 years of dialysis know-how to develop an AI-powered digital platform that not only reduces hospital stays but has decreased the mortality rate, predicting thrombotic events before they occur. M42 has also developed and deployed the Med42 LLM model, a large language model designed for clinical use cases and available for research use as an open-source solution. The company's AIRIS-TB conducts 2,000 AI-powered chest X-ray examinations daily to screen for tuberculosis against 200 conducted via conventional methods.
